Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma

BACKGROUND: Cytotoxic chemotherapy (CC) is currently used in metastatic melanoma after patients have developed resistance to immune checkpoint inhibitors (ICI) and/or Mitogen‐Activated Protein Kinase inhibitors (MAPKi). We sought to evaluate if a previous treatment by ICI or MAPKi influences clinica...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Med
Autors principals: Mangin, Marie‐Alix, Boespflug, Amélie, Maucort Boulch, Delphine, Vacheron, Charles‐Hervé, Carpentier, Isabelle, Thomas, Luc, Dalle, Stéphane
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Clinical Cancer Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8124115/
https://ncbi.nlm.nih.gov/pubmed/33932099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3760
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars